Back
NM_000314.8:c.-361C>T
p.? · PTEN
0%
complete
Final classification
VUS
BS1
PTEN
c.-361C>T
p.?
This variant

The PTEN NM_000314.8:c.-361C>T (NP_000305.3:p.?) variant has not been reported in ClinVar.

Transcript
NM_000314.8
HGVS · transcript:coding
NM_000314.8:c.-361C>T
GRCh38
chr10:87864109 C>T
GRCh37
chr10:89623866 C>T
Richards et.al., 2015 - Combining rules v3.2.0 criteria-combination framework was evaluated deterministically with applied criteria: BS1 supporting; no rule matched the adjudicated criteria.
Classification rationale
BS1 VUS
PTEN c.-361C>T

The PTEN NM_000314.8:c.-361C>T (NP_000305.3:p.?) variant has not been reported in ClinVar.1 This variant is absent from gnomAD v2.1 but present in gnomAD v4.1 at 6/492096 alleles, with filtering allele frequency 6.24e-06; this is above the PTEN PM2 cutoff and within the PTEN BS1_supporting frequency range.2

BS1 VUS
LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
Gene diagram · NM_000314.8 · variants mapped to exon structure
PTEN NM_000314.8
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 16 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 1
Strength Supporting Moderate Strong Very strong
BS1 supporting review Benign
The gnomAD v4.1 filtering allele frequency is 6.24e-06, which falls within the PTEN BS1_Supporting range of 0.0000043 to 0.000043 and below the BS1 strong range of 0.000043 to 0.00056; therefore BS1 is met at supporting strength.
gnomAD v4.1 joint grpmax FAF is 6.24e-06.
Assessed · not applied · 4 not met · 12 not assessed
Pathogenic
PVS1 This 5'UTR variant does not fall into the PTEN PVS1 decision tree categories for nonsense, frameshift, canonical +/-1,2 splice, or exon-level loss-of-function variants, so PVS1 is not met.
PS1 No previously established pathogenic variant causing the same amino acid change or an equivalent pathogenic splicing effect at this nucleotide was identified, so PS1 was not assessed.
PS2 No confirmed de novo occurrence in an affected individual was identified, so PS2 was not assessed.
PS3 No well-established functional study showing a damaging effect of this exact 5'UTR variant on PTEN splicing, transcript abundance, or gene function was identified, so PS3 was not assessed.
PS4 No enrichment data or counted affected probands meeting PTEN VCEP PS4 specifications were identified for this variant, so PS4 was not assessed.
PM2 This variant is absent from gnomAD v2.1 but is present in gnomAD v4.1 at AF 1.21927e-05, with highest subpopulation AF 4.45315e-05, which is above the PTEN PM2 threshold of <0.00001 overall and <0.00002 within a subpopulation when multiple alleles are observed; therefore PM2 is not met.
PM6 No presumed de novo occurrence without parental confirmation was identified, so PM6 was not assessed.
PP1 No segregation data were identified for this variant, so PP1 was not assessed.
PP3 The PTEN VCEP applies PP3 to concordant SpliceAI and VarSeak splicing predictions for synonymous or intronic variants, or to missense variants with REVEL >0.7.
Benign
BA1 The gnomAD v4.1 filtering allele frequency for this variant is 6.24e-06, which is below the PTEN BA1 threshold of >0.00056, so BA1 is not met.
BS2 No homozygous observation in a healthy or PTEN hamartoma tumor syndrome-unaffected individual was identified, so BS2 is not met.
BS3 No well-established study showing no damaging effect of this exact 5'UTR variant on PTEN function or splicing was identified, so BS3 was not assessed.
BS4 No lack-of-segregation evidence was identified for this variant, so BS4 was not assessed.
BP2 No observation of this variant in trans with a pathogenic PTEN variant, or at least three cis/phase-unknown observations with different pathogenic PTEN variants, was identified, so BP2 was not assessed.
BP4 The PTEN VCEP applies BP4 to synonymous or intronic variants with concordant benign SpliceAI and VarSeak splicing predictions, or to missense variants with REVEL <0.5.
BP5 No alternate molecular diagnosis with non-overlapping phenotype was identified, so BP5 was not assessed.
N/A · 11 PM1 · PM3 · PM4 · PM5 · PP2 · PP4 · PP5 · BP1 · BP3 · BP6 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 1.21927e-05; MAF= 0.00122%, 6/492096 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 4.45315e-05; MAF= 0.00445%, 1/22456 alleles, homozygotes = 0); grpmax FAF= 6.24e-06.
v2.1
Absent from gnomAD v2.1.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.0012% · 6 / 492,096
0 hom · FAF 0.00062%
Remaining individuals
1 / 22,456
0.0045%
European (non-Finnish)
5 / 279,178
0.0018%
+ 8 not observed (Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant is absent from ClinVar.
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).
Functional No data
No calibrated functional assay or RNA evidence was identified for this variant.
OncoKB ↗
COSMIC screenshot
COSMIC
Somatic evidence
COSMIC
This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant cancer hotspot.
COSMIC ↗
Sources & reference links
7Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
SpliceAI
OncoKB
COSMIC